U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT06926673) titled 'Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3' on April 11.
Brief Summary: This study is a sub-study of the master protocol 205801 (NCT03739710). This sub study will assess safety and pharmacokinetics and pharmacodynamics (PK/PD) of novel regimens (Dostarlimab plus belrestotug , and Dostarlimab plus belrestotug plus nelistotug) in participants with previously treated NSCLC.
Study Start Date: Dec. 23, 2021
Study Type: INTERVENTIONAL
Condition:
Neoplasms
Intervention:
DRUG: Dostarlimab
Dostarlimab will be administered
DRUG: Belrestotug.
Be...